Search results
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 10 hours agoThe company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...
Want to show teachers appreciation? A top Florida school gives them more freedom
WJHL· 2 days agoWaning job satisfaction over the last two decades has accompanied a decline in teachers’ sense of...
Is Wegovy or Ozempic Better for Weight Loss?
MediaFeed via AOL· 5 days agoJacob Wackerhausen/Istockphoto The most common side effects of Ozempic include: Pancreatitis (inflammation of the pancreas) Diabetic retinopathy...
5 health behaviors that can make you blind
Rolling Out· 16 hours agoMost of us are aware that certain diseases or injuries can lead to vision loss but not realize that everyday behaviors can also harm our sight.
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 2 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
HanAll Biopharma initiates Phase III DED treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoHanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical...
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Market Watch· 2 days agoEyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
NovaBay reports record Avenova sales on Amazon By Investing.com
Investing.com· 15 hours agoNovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has announced a significant uptick in sales for...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 6 days agoRegeneron stock jumped Thursday, bolstered by strong sales of a high-dose version of its blockbuster...
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...
Benzinga· 6 days agoThursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...
